Visfatin as a marker of endothelial dysfunction in pediatric kidney transplant recipients /
Marwa Khaled Sayed Abdelshafy
Visfatin as a marker of endothelial dysfunction in pediatric kidney transplant recipients / الفيسفاتين كدلالة خلل البطانية فى الأطفال المتلقين لزراعة الكلى Marwa Khaled Sayed Abdelshafy ; Supervised Fatina Ibrahim Fade , Hafez Mahmoud Bazaraa , Mohamed Gamal Shouman - Cairo : Marwa Khaled Sayed Abdelshafy , 2014 - 163 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pediatrics
Kidney transplantation is treatment of choice for pediatric end stage renal disease. In this study, Visfatin serum level has been evaluated (in 30 hemodialysis patients, 36 transplant recipients, and 30 controls), as a measure for endothelial dysfunction, and has been compared to brachial artery flow mediated dilatation. Visfatin level in transplant recipients [median (IQR) of 4 (3.5-5.8) ng/ml], was significantly (p<0.0001) lower than the hemodialysis group [median (IQR) of 65 (30-70) ng/ml], and not significantly different from controls [median (IQR) of 5 (2.4-6) ng/ml)]. Flow mediated dilatation was also better in transplant recipients. No direct statistical correlation could be reached between Visfatin level and flow-mediated dilatation. Endothelial dysfunction is significantly improved in transplant recipients
Chronic kidney disease End-stage renal disease Endothelial dysfunction
Visfatin as a marker of endothelial dysfunction in pediatric kidney transplant recipients / الفيسفاتين كدلالة خلل البطانية فى الأطفال المتلقين لزراعة الكلى Marwa Khaled Sayed Abdelshafy ; Supervised Fatina Ibrahim Fade , Hafez Mahmoud Bazaraa , Mohamed Gamal Shouman - Cairo : Marwa Khaled Sayed Abdelshafy , 2014 - 163 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pediatrics
Kidney transplantation is treatment of choice for pediatric end stage renal disease. In this study, Visfatin serum level has been evaluated (in 30 hemodialysis patients, 36 transplant recipients, and 30 controls), as a measure for endothelial dysfunction, and has been compared to brachial artery flow mediated dilatation. Visfatin level in transplant recipients [median (IQR) of 4 (3.5-5.8) ng/ml], was significantly (p<0.0001) lower than the hemodialysis group [median (IQR) of 65 (30-70) ng/ml], and not significantly different from controls [median (IQR) of 5 (2.4-6) ng/ml)]. Flow mediated dilatation was also better in transplant recipients. No direct statistical correlation could be reached between Visfatin level and flow-mediated dilatation. Endothelial dysfunction is significantly improved in transplant recipients
Chronic kidney disease End-stage renal disease Endothelial dysfunction